Loading...
•
Sep 30, 2020
uniQure Q3 2020 Earnings Report
Reported financial results for the third quarter of 2020 and highlighted recent progress across its business.
Key Takeaways
uniQure reported revenue of $1.8 million and a net loss of $53.8 million for the third quarter of 2020. The company held cash and cash equivalents of $279.5 million as of September 30, 2020.
Enrolled first four patients in Phase I/II Clinical Trial of AMT-130 in Huntington’s Disease
Top-Line Data from HOPE-B Pivotal Trial in Hemophilia B Expected Before Year End
Initiated IND-enabling Studies for AMT-150 in Spinocerebellar Ataxia Type 3 (SCA3)
All 54 patients in the HOPE-B pivotal trial of etranacogene dezaparvovec have now completed their 26-week follow-up visits
Forward Guidance
uniQure expects to announce top-line data from the HOPE-B pivotal trial before the end of the year and complete enrollment of the first dose cohort in the Phase I/II trial of AMT-130 by mid-2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...